HAEMATOLOGICAL CHANGES AND MORTALITY IN SARS-CoV-2 PATIENTS

MAFALDA URBANO¹, ELÍSIO COSTA², CATARINA GERALDES³

1- Clinical Hematology Intern, Coimbra University Hospital Center, Coimbra, Portugal; 2- UCIBIO/REQUIMTE, PORTO4AGEING - Competences Centre on Active and Healthy Ageing, Faculty of Pharmacy, University of Porto, Porto, Portugal; 3- MD, PhD, Coimbra University Hospital Center (CHUC); Faculty of Medicine, University of Coimbra (FMUC), Coimbra Institute for Clinical and Biomedical Research (iCBR);

INTRODUCTION

The severe acute respiratoy syndrome 2 (SARS-CoV-2) has been associated with leukopenia, lymphopenia and hypercoagulability. This study aims to clarify if we can use

METHODS

We selected all patients who had a SARS-CoV-2 positive test and hemogram between the 15th of March and the 15th of April 2020. Clinical data were obtained from all 274 SARS-CoV-2

some blood parameters to facilitate diagnosis and estimate prognosis.

positive patients admited at two portuguese public hospitals. A multivariate analysis was then preformed using the clinical significant variables in SPSS v.26.0. Statistical significance defined at p<0,05.

RESULTS

Analyzing the association between mortality and all studied
variables we used unadjusted and adjusted models. The
unadjusted model showed a correlation between mortality and:
age, leukocyte count, neutrophil count, lymphocyte count,
erythrocytes and platelets counts, neutrophil/lymphocyte ratio,
hemoglobin concentration, MCHC and LDH levels.
In the adjusted model some independent predictors of
mortality were evident: age (OR=0.046, p<0.001), gender

	All cases (N=274)	Death		
		No (n=191)	Yes (n=83)	P value
Age, years	76.0 (63.0-85.5)	71.0 (52.0–82.0)	83.0 (77.0-88.5)	<0.001
Sex, % male	42.4% (n=114)	23.9% (n=44)	48.2% (n=41)	0.236
Leucocytes (x10 ⁹ /L)	6.7 (5.0-9.4)	6.2 (4.9-8.3)	8.9 (6.2-11.0)	<0.001
Neutrophils(x1 0 ⁹ /L)	3.5 (1.4-6.9)	3.4 (1.6-5.2)	4.9 (1.1-8.2)	0.146
Lymphocytes (x10 ⁹ /L)	1.7 (1.1-3.1)	1.7 (1.1-2.6)	1.6 (0.7-5.3)	0.901
Platelets (x10 ⁹ / L)	209.7 +/- 5.7	221.5 +/- 6.7)	184.1 +/- 9.9	0.002
Neutrophils/ leucocytes	4.1 (2.4-7.3)	3.5 (2.2-5.7)	7.1 (3.3-13.3)	<0.001
Erythrocytes (x10 ¹² /L)	4.1+/- 0.5	6.0 +/- 1.8	3.8 +/- 0.1	0.214
Haemoglobin (g/dL)	12.0+/- 0.1	12.4 +/-0.1	11.2 +/-0.2	<0.001
MCHC (g/dL)	33.3 +/- 0.1	33.5 +/- 0.1	32.8+/- 0.1	<0.001
LDH (U/L)	315.0+/- 8.5	287.1 +/-8.5	371.8 +/- 17.3	<0.001

(OR=0.2364, p=0.045), platelets OR=9.106, p=0.001, lymphocyte count (OR=0.194, p=0.033), neutrophil count (OR=0.062, p=0.003), neutrophil/lymphocyte ratio (OR=0.098, p=0.002), erythrocytes count (OR=9.021, p<0.001) and MCHC are independently associated with mortality (OR=7.016, p=0.007).

Tabel 1. Comparison between 'death' vs 'no death'. MCHC (molecular corpuscular hemoglobin concentration) ; LHD (lactate dehydrogenase)

Patients with neutrophil counts higher than 5.91 $\times 10^{9}$ /L have a risk of mortality 16 times higher than those with less than 1.36 $\times 10^{9}$ /L; Patients with lymphocyte count higher than 3.05 $\times 10^{9}$ have a risk of mortality 5 times higher than those with lymphocytes counts less than 1.04 $\times 10^{9}$ /L; platelet counts less than 147 $\times 10^{9}$ /L showed a mortality risk 9.1 times higher when compared with those with platelet counts higher than 257 $\times 10^{9}$ /L.



Haematological data at admission in the health care system can predict mortality of SARS-CoV-2 infection and

we recommend it's use in clinical decisions and patients' prognosis evaluation.



REFERENCES



www.iachlive.cme-congresses.com